Becton, Dickinson and Company (BDX)
NYSE: BDX · Real-Time Price · USD
224.10
-1.05 (-0.47%)
At close: Nov 18, 2024, 4:00 PM
224.60
+0.50 (0.22%)
After-hours: Nov 18, 2024, 7:52 PM EST

Company Description

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide.

The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional. The BD Medical segment provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication safety and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; and prefillable drug delivery systems.

The BD Life Sciences segment offers specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers.

The BD Interventional segment provides hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention; peripheral intervention products; and urology and critical care products.

The company was founded in 1897 and is headquartered in Franklin Lakes, New Jersey.

Becton, Dickinson and Company
Becton, Dickinson and Company logo
Country United States
Founded 1897
IPO Date Apr 23, 1962
Industry Medical Instruments & Supplies
Sector Healthcare
Employees 73,000
CEO Thomas Polen

Contact Details

Address:
1 Becton Drive
Franklin Lakes, New Jersey 07417-1880
United States
Phone 201 847 6800
Website bd.com

Stock Details

Ticker Symbol BDX
Exchange NYSE
Fiscal Year October - September
Reporting Currency USD
CIK Code 0000010795
CUSIP Number 075887109
ISIN Number US0758871091
Employer ID 22-0760120
SIC Code 3841

Key Executives

Name Position
Thomas E. Polen Jr. President, Chief Executive Officer and Chairman
Shana Carol Neal Executive Vice President and Chief People Officer
Michael Garrison Executive Vice President and President of Medical segment
Thomas J. Spoerel Senior Vice President, Controller and Chief Accounting Officer
Elizabeth McCombs Executive Vice President and Chief Technology Officer
Dr. Joseph M. Smith F.A.C.C, M.D., Ph.D. Senior Vice President, Chief Scientific Officer and Co-Chair of Scientific Advisory Board
Denise Russell Fleming Executive Vice President of Technology and Global Services and Chief Information Officer
Greg Rodetis Head of Investor Relations
Michelle Quinn Executive Vice President and General Counsel
Claudia Curtis Senior Vice President, Chief Ethics and Compliance Officer

Latest SEC Filings

Date Type Title
Nov 7, 2024 8-K Current Report
Oct 2, 2024 8-K Current Report
Sep 16, 2024 144 Filing
Aug 30, 2024 8-K Current Report
Aug 1, 2024 10-Q Quarterly Report
Aug 1, 2024 8-K Current Report
Jul 12, 2024 8-K Current Report
Jun 27, 2024 11-K Annual report of employee stock purchase, savings and similar plans
Jun 27, 2024 11-K Annual report of employee stock purchase, savings and similar plans
Jun 12, 2024 CERT Certification by an exchange approving securities for listing